Presented at #ASCO24: Among patients with EGFR-mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo. Full LAURA trial results: nej.md/451OXwi

🚨🚨🚨 #ESOPEC🚨🚨🚨 🔥Practice shifting trial🔥 Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma Randomized Peri-op FLOT (FLOT4) vs Pre-operative chemoradiation (CROSS) Congrats to the study investigators! Let’s dive in! #ASCO24 Mayo Clinic Radiation Oncology 1/

📢 plenary #ASCO24 LAURA ph III RCT!! 👏🏽👏🏽 Suresh S. Ramalingam, MD, FASCO ➡️ n=216, adjuvant osimertinib after chemoRT for stage III #lungcancer ➡️ astonishing PFS HR 0.16💥 ➡️ immature survival outcomes, trend at HR 0.81 ➡️ ≥Grade 3 AEs in 35% vs 12% ➡️ crossover to osi allowed #lcsm #radonc

Good but I always have problem finding details about radiotherapy details even at #ASCO24 Laura is here to stay though

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 Lecia Sequist, MD, MPH

📢🚨#ASCO24 plenary David R. Spigel, MD, FASCO - pivotal ADRIATIC ph III trial; adjuvant durvalumab arm after chemoradiotherapy (cCRT) ± PCI in small cell #lungcancer; ⬆️ OS (HR 0.73), median OS 55.9 vs 33.4 for placebo. Grade 3/4 AEs in 24.3% vs 24.2%. 💥Practice changing!!! #radonc #lcsm

#ASCO24 #LAURA I’m putting this 👏standing ovation video out here for all the patients and investigators who participated in this practice changing study. ➡️ But, let’s all remember that we can’t celebrate until all patients get #biomarkertesting and access to these life-saving

The new standard of care is consolidation immunotherapy for limited stage small cell lung cancer & the first systemic therapy advance for limited small cell in ~50yrs. Allied to Laura we had fun on the ASCO non-metastatic NSCLC/SCLC/meso track committee this year! #lcsm #ASCO24

Continuing immunotherapy beyond 2 years is not without risk 🚨50% develop late IRAE, post 2yrs 🚨60% of these had no pre-2yr IRAE 🚨Female, non-causcasian = higher risk Abstract 8551 #ASCO24 #LCSM

Narlal2 phase III dose escalation trial . 350 patients randomized end point loco regional kontrol, significantly positive for escalation arm #ASCO24

I needed to hear this Maybe you do too

An important clarification for the #ASCO24 audience re PFS. When people say PFS is a meaningful endpoint in itself, people are making a fallacious assumption that “all PFS events are created equal”. This is untrue. I believe people are suggesting that delaying PFS

Miss #ASCO24 or just didn’t make every education session you wanted to see? Check out the #ASCOEdBook articles from the session faculty, they are free for everyone even if you didn’t attend!

NARLAL ll OS phase lll in comparison to the coast trial OS phase ll “dual” immunotherapy trial in stage lll NSCLC

Great results , would have been more informative with some standard radiotherapy details . Can we advocate for minimum standard about radiotherapy information presented at #ASCO24 ?!

Book-release🤩 The first Danish ACP-textbook will be out 24th June! Please, give notice if you are coming to the release: survey.au.dk/LinkCollector?… Read more about the book: bit.ly/3xRqv4g Mette Kjærgaard Nielsen Palliative Care Research Aarhus Department of Oncology, Aarhus University Hospital Aarhus Uni.hospital Aarhus University Aarhus Universitet

I don’t know who else needs to hear this, but I know I did

smart approach

Thoracic #RadOncs - check out our new paper in JACC CardioOnc! Simple heart features on planning CT were associated with risk of specific cardiac events after RT for NSCLC (n=478) Is it time we got Cardiology input on some of our patients? Thread (/14)...

That was emotional ❤️